Literature DB >> 2013440

Primary surgical therapy of ovarian cancer: how much and when.

M E Potter1, E E Partridge, K D Hatch, S J Soong, J M Austin, H M Shingleton.   

Abstract

From July 1975 through December 1985, 328 patients with ovarian malignancies were treated. Of these, 302 had epithelial invasive malignancies and constitute the study group. The impact of the operative procedure, findings, and subsequent treatment is evaluated. Patients who underwent extensive debulking procedures such as bowel resection and peritoneal stripping did not have improved survival compared with those patients who did not undergo these procedures and yet had residual disease remaining (P = 0.7 and P = 0.34). Reoperating patients felt to be unresectable at the time of referral did not increase survival over reoperating patients after an attempt at chemotherapeutic reduction (P = 0.34).

Entities:  

Mesh:

Year:  1991        PMID: 2013440     DOI: 10.1016/0090-8258(90)90277-r

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Authors:  Amin P Makar; Claes G Tropé; Philippe Tummers; Hannelore Denys; Katrien Vandecasteele
Journal:  Oncologist       Date:  2016-03-23

Review 2.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Christine Ang; Karen K L Chan; Andrew Bryant; Raj Naik; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

3.  p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.

Authors:  G Ferrandina; A Fagotti; M G Salerno; P G Natali; M Mottolese; F Maneschi; A De Pasqua; P Benedetti-Panici; S Mancuso; G Scambia
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

Review 4.  MR imaging in ovarian cancer.

Authors:  S A A Sohaib; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.